EU Authorised Representative for Medical Devices and IVDs Across Europe
For manufacturers based outside the European Union, bringing medical devices or in vitro diagnostic devices into the European market involves more than product quality, technical documentation and regulatory preparation. Before a device can be placed on the European market, the manufacturer must appoint an EU Authorized Representative who is physically located in the European Union and legally recognised as the manufacturer’s official representative. This role is essential under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation because regulators need a responsible local party who can communicate, provide documentation and support compliance activities when required. An eu-authorized-representative is far more than just a name printed on a label. They serve as the legal presence of a non-EU manufacturer and play a vital role in ensuring market access, regulatory trust and ongoing post-market accountability.
Why an EU Authorized Representative Is Required
European medical device rules are designed to protect patients, healthcare professionals and users by ensuring that every product placed on the market has a clear chain of responsibility. If a manufacturer operates outside the European Union, regulators cannot always interact with them as easily as they would with a locally established company. This is where the EU Authorized Representative becomes necessary. The representative provides a formal local presence and serves as the official point of communication for Competent Authorities, Notified Bodies and other regulatory stakeholders.
Without appointing an authorised representative, a non-EU manufacturer cannot legally place medical devices or IVDs on the European market. This requirement applies across a broad spectrum of products, from low-risk devices to advanced diagnostic technologies. The requirement exists before market entry, which means the representative must be appointed early in the compliance process rather than treated as a final administrative step. For companies preparing for European distribution, selecting the right EU Authorized Representative for Medical Devices and IVDs can significantly influence registration readiness, document management and long-term regulatory stability.
The Written Mandate Between Manufacturer and Representative
The connection between the manufacturer and the EU Authorized Representative must be formalised through a written mandate. This document outlines the activities the representative is permitted to carry out and confirms the responsibilities of both parties. It is a key compliance document because it sets out the scope of representation, responsibilities, communication duties and actions required if compliance concerns arise.
An unclear or weakly drafted mandate can cause uncertainty at critical moments, particularly during authority requests, inspections, complaint handling or corrective actions. A strong mandate should clearly describe how documents will be made available, how regulatory communication will be handled, how incident information will be shared and what happens if the manufacturer does not meet its duties. Therefore, the mandate must be carefully drafted and reviewed before registration or market entry begins.
Label and Packaging Requirements
The name and address of the EU Authorized Representative must appear on the device label, packaging or related product information as required by the applicable regulation. This enables authorities, distributors, healthcare professionals and users to identify the local representative connected to the device. It also strengthens the representative’s role as the official European contact for a manufacturer based outside the European Union.
Accurate labelling is essential because incorrect or missing representative details can lead to compliance issues and possible delays in market access. Manufacturers must ensure that artwork, instructions, declarations and registration data are consistent before product release. If the representative changes, labelling and registration details may also need to be updated in a controlled and timely manner.
Documentation Review and Availability
A key responsibility of an EU Authorized Representative for Medical Devices and IVDs is to ensure that essential compliance documents are available and correctly prepared. This includes checking that the EU Declaration of Conformity exists, that technical documentation has been compiled and that the manufacturer has followed an appropriate conformity assessment route for the device type and risk class.
The representative may also need to hold or have access to copies of technical documentation, declarations and Notified Body certificates. These documents must be available for inspection by Competent Authorities for the required retention period after the last device has been placed on the market. This makes document control a central part of the relationship between manufacturer and representative. Manufacturers should keep records updated and ensure the representative can respond promptly to regulatory requests.
Communication With Competent Authorities and Notified Bodies
The EU Authorized Representative acts as the official communication channel between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests information, samples, technical documentation or clarification, the representative is expected to support the response process. The representative may also liaise with Notified Bodies when necessary, particularly regarding certification, conformity assessments or corrective measures.
This communication role requires more than forwarding messages. A dependable representative should understand regulatory requirements, maintain accurate records and ensure responses are delivered within required timelines. Delayed or incomplete responses can create serious issues for manufacturers, including market restrictions or further regulatory review. For this reason, manufacturers should work with a representative who has strong regulatory knowledge and clear internal processes.
Post-Market Surveillance and Incident Support
Medical device compliance does not end after market entry. Once a device is in use, manufacturers must continue monitoring performance, complaints, incidents and safety signals. The EU Authorized Representative has a role in supporting this post-market responsibility by passing complaints and incident information to the manufacturer without delay.
This is especially important when information comes from clinicians, patients, users, distributors or authorities. Timely reporting allows the manufacturer to determine whether investigation, reporting, field safety actions or corrective measures are required. A strong representative understands that post-market surveillance is not just paperwork. It plays a key role in patient safety, product enhancement and continued regulatory confidence.
Registration Responsibilities and EUDAMED
Under European regulatory systems, manufacturer and eu-authorized-representative representative details must be registered as required. The EU Authorized Representative may support the registration of both the manufacturer and representative information in EUDAMED. Accurate registration enables authorities to identify responsible entities, review device data and maintain market supervision.
Manufacturers should prepare complete company details, device information, certificates and declarations before registration activities begin. Any inconsistency between labels, declarations, technical files and registration records can create delays or compliance questions. The representative’s involvement helps ensure that required information is properly aligned and available when needed.
When the Representative Must Take Action
An EU Authorized Representative also carries responsibilities if the manufacturer does not fulfil regulatory requirements. If significant non-compliance arises and is not corrected by the manufacturer, the representative may need to terminate the mandate and notify relevant authorities and the Notified Body where relevant. This responsibility highlights that the role extends beyond administrative tasks.
The representative has legal accountability and cannot ignore major compliance failures. Manufacturers should therefore treat the representative as a regulatory partner rather than a passive service provider. Open communication, timely document updates and clear responsibility sharing help prevent misunderstandings and reduce risk during the product life cycle.
Choosing the Right EU Authorized Representative
Choosing an EU Authorized Representative requires careful consideration. Manufacturers should evaluate regulatory expertise, experience in medical devices and IVDs, document management capabilities, clear response processes and strong knowledge of European regulations. The representative should be able to support communication with authorities, maintain records and guide the manufacturer on practical compliance expectations.
Cost alone should not determine the choice. A weak representative can create delays, poor communication and unnecessary risk, while a capable representative can help maintain confidence throughout market entry and post-market activities. The correct selection provides non-EU manufacturers with a reliable European presence and enables smoother regulatory management.
Conclusion
An EU Authorized Representative is a mandatory requirement for non-EU manufacturers aiming to introduce medical devices or IVDs into the European market. The role includes legal representation, documentation availability, authority communication, complaint handling, registration support and action in cases of serious non-compliance. Under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is mandatory and must be done before market entry. By selecting a capable EU Authorized Representative for Medical Devices and IVDs, manufacturers can enhance compliance, protect patient safety and establish a solid foundation for long-term European market access.